Denali Therapeutics annual meeting results: directors elected, auditor ratified

Denali Therapeutics Inc.

Electors voted to re-elect three Class III directors: Jennifer Cook, David Schenkein, and Ryan J. Watts.
Ernst & Young LLP ratified as independent auditor for FY 2023 with 112,694,203 votes for.
Advisory vote on executive compensation approved with 98,002,580 votes for.
82.58% of outstanding shares (112,922,471) were represented at the meeting.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Denali Therapeutics Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2023-06-01 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-06-01

Exact text from the filing

Proposal 2 - Ratification of Appointment of Independent Registered Public Accounting Firm The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was ratified based on the following results of voting: For Against Abstain Broker Non-Votes 112,694,203 198,540 29,728 —

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Denali Therapeutics Inc. shareholders approved Advisory Vote to Approve Executive Compensation at the 2023-06-01 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2023-06-01

Exact text from the filing

Proposal 3 - Advisory Vote to Approve Executive Compensation The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement. For Against Abstain Broker Non-Votes 98,002,580 6,571,884 50,220 8,297,787

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Denali Therapeutics Inc. shareholders approved Election of three Class III directors to hold office until the 2026 annual meeting of stockholders. at the 2023-06-01 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-06-01

Exact text from the filing

Proposal 1 - Election of Directors Election of three Class III directors to hold office until the 2026 annual meeting of stockholders. Each of the following nominees was elected to serve as a Class III director, to hold office until the Company’s 2026 annual meeting of stockholders or until his or her respective successor has been duly elected and qualified or his or her earlier resignation or removal. Nominees For Withheld Broker Non-Votes Jennifer Cook 87,451,911 17,172,773 8,297,787 David Schenkein, M.D. 87,642,096 16,982,588 8,297,787 Ryan J. Watts, Ph.D. 103,702,078 922,606 8,297,787

View on SEC.gov

Browse all shareholder votes →

Denali Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001714899-23-000079

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.